Antiphospholipid syndrome (APS), also known as Hughes syndrome, is an autoimmune disease characterised by thrombophilia. Cumulative haematologic/clinical manifestations include venous thrombosis (37%) or arterial thrombosis (27–49%), cytopenia (30–38%), complications during pregnancy (55–74%), neurological (66%) and cardiac (27%) involvement, as well as pulmonary (20–30%) or cutaneous (40%) tissue damage due to the underlying circulatory disorders.
APS is classified as primary (pAPS) or secondary (sAPS). Both forms present the same type of immune and haematologic response; however, in sAPS this response is a secondary manifestation to another autoimmune disorder or a specific pathological condition.
A final diagnosis of APS requires at least one clinical criterion (thrombosis or complications during pregnancy) and one laboratory criterion (medium-to-high antibody titres in serum/plasma at an interval of at least 12 weeks).
Antibodies against β2-GP1 are specific markers for both pAPS and sAPS. The ACR/EULAR classification criteria for the diagnosis of APS include the serological determination of anti-β2-GP1 as a laboratory criterion. Anti-β2-GP1 testing is crucial to confirm suspected APS cases that are negative for anticardiolipin antibodies or lupus anticoagulant.
IgG and/or IgM antibodies against β2-GP1 are present in 30–80% of APS patients.
Siero, plasma EDTA, plasma eparinato, plasma citrato
ELISA
A digiuno per circa 8-12 ore prima del prelievo
Per la conservazione del campione consultare la Carta Servizi
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Iscriviti alla nostra newsletter per rimanere sempre aggiornato.